Towards personalised treatment in primary Sjögren's syndrome: baseline parotid histopathology predicts responsiveness to rituximab treatment

EULAR Sjögren's syndrome disease activity index: development of a consensus systemic disease activity index for primary Sjögren's syndrome

Raphaèle Séror, Philippe Ravaud, Simon Bowman et al. · Annals of the Rheumatic Diseases · 2009 · 945 citations · Full text

Life Sciences, Immunology, Internal Medicine +16

Autoimmune disorders and risk of non-Hodgkin lymphoma subtypes: a pooled analysis within the InterLymph Consortium

Karin E. Smedby, Claire M. Vajdic, Michael O. Falster et al. · Blood · 2008 · 624 citations · Full text

Life Sciences, Immunology, Oncology +15

Lymphoma and other malignancies in primary Sjögren's syndrome: a cohort study on cancer incidence and lymphoma predictors

Elke Theander · Annals of the Rheumatic Diseases · 2005 · 568 citations · Full text

Medicine, Immunology, Oncology +17

Importance of Cellular Microenvironment and Circulatory Dynamics in B Cell Immunotherapy

Qian Gong, Qinglin Ou, Shiming Ye et al. · The Journal of Immunology · 2005 · 540 citations · Full text

Life Sciences, Cell Biology, Immunology +16

Rituximab treatment in patients with primary Sjögren's syndrome: An open‐label phase II study

Justin Pijpe, Gustaaf W. van Imhoff, Fred K. L. Spijkervet et al. · Arthritis & Rheumatism · 2005 · 495 citations

Life Sciences, Clinical Sciences, Immunology +15